Zydus Lifesciences Ltd reported a healthy operational performance for the quarter ended March 31, 2026, driven by strong revenue growth and margin expansion.
The company posted a consolidated net profit of ₹1,272.5 crore in Q4 FY26, compared to ₹1,170.9 crore in the corresponding quarter last year, registering a growth of 8.7% year-on-year.
Revenue from operations rose to ₹7,587 crore during the quarter from ₹6,527.9 crore in Q4 FY25, marking an increase of 16.2% YoY.
Operationally, EBITDA stood at ₹2,554 crore in the March quarter, compared to ₹2,125.5 crore reported a year ago, reflecting a growth of 20.2% YoY. EBITDA margin improved to 33.7% from 32.6% in the year-ago period.
Total income for the quarter came in at ₹7,721.2 crore, while total expenses stood at ₹5,664 crore.
Profit before tax and share of profit of joint ventures stood at ₹1,659.7 crore in Q4 FY26 compared with ₹1,672 crore in the corresponding quarter last year. Tax expenses during the quarter were reported at ₹318.4 crore.
Employee benefit expenses rose to ₹1,238.8 crore from ₹971.4 crore in Q4 FY25, while other expenses stood at ₹2,464 crore against ₹1,694.5 crore reported in the year-ago quarter.
Earnings per share (EPS) for the quarter came in at ₹12.65 compared with ₹11.64 in the corresponding quarter last year.
Total comprehensive income for the quarter stood at ₹857.6 crore compared with ₹1,220.9 crore in Q4 FY25.